- Home
- SON vs VKTX Comparison
SON vs VKTX Comparison
Compare SON & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SON
- VKTX
- Stock Information
- Founded
- SON 1899
- VKTX 2012
- Country
- SON United States
- VKTX United States
- Employees
- SON N/A
- VKTX N/A
- Industry
- SON Containers/Packaging
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- SON Consumer Discretionary
- VKTX Health Care
- Exchange
- SON Nasdaq
- VKTX Nasdaq
- Market Cap
- SON 5.1B
- VKTX 4.6B
- IPO Year
- SON N/A
- VKTX 2015
- Fundamental
- Price
- SON $49.40
- VKTX $42.25
- Analyst Decision
- SON Buy
- VKTX Strong Buy
- Analyst Count
- SON 5
- VKTX 12
- Target Price
- SON $59.00
- VKTX $106.75
- AVG Volume (30 Days)
- SON 748.4K
- VKTX 3.8M
- Earning Date
- SON 02-12-2025
- VKTX 02-05-2025
- Dividend Yield
- SON 4.21%
- VKTX N/A
- EPS Growth
- SON N/A
- VKTX N/A
- EPS
- SON 2.91
- VKTX N/A
- Revenue
- SON $6,572,688,000.00
- VKTX N/A
- Revenue This Year
- SON N/A
- VKTX N/A
- Revenue Next Year
- SON $1.53
- VKTX N/A
- P/E Ratio
- SON $16.98
- VKTX N/A
- Revenue Growth
- SON N/A
- VKTX N/A
- 52 Week Low
- SON $48.22
- VKTX $17.23
- 52 Week High
- SON $61.73
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- SON 38.77
- VKTX 33.93
- Support Level
- SON $49.04
- VKTX $37.80
- Resistance Level
- SON $51.48
- VKTX $48.55
- Average True Range (ATR)
- SON 1.11
- VKTX 2.54
- MACD
- SON -0.22
- VKTX -0.45
- Stochastic Oscillator
- SON 9.65
- VKTX 30.11
About SON Sonoco Products Company
Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.